Medical Greens announces start of distribution of Dharmanol
Published 16 December 2013
SK3 Group’s subsidiary Medical Greens has announced that the first batch of Dharmanol has been manufactured and is ready to be rolled out for California distribution.
Dharmanol (pronounced DAR-mah-nol) will be available in two forms: low-dose, non-psychoactive tablets and high-doses directed to cancer.
The low-dose, non-psychoactive tablets can be taken daily as a nutritional supplement to stimulate the endo-cannabinoid system, an internal system which controls and regulates many other bodily systems such as immune response.
Much research has shown that there is substantial medicinal benefit in 'stimulating' a compromised endo-cannabinoid system with cannabinoids, causing the other systems to work as they should.
At the opposite end of the spectrum is using Dharmanol for cancer. Very large doses can be taken daily with no psychoactive effects.
On observing the spectacular results that patients are receiving with standard Simpson therapy, most scientists studying cannabis medicine agree that if the dose could be increased ten or a hundred times, its already substantial efficacy will be greatly increased.
Now this is possible thanks to the removal of the "high" from the cannabinoids in the production of Dharmanol.
These tablets contain an array of the most beneficial non-psychoactive cannabinoids. Each tablet will contain 5mg. of CBD, 5mg. of mixed cannabinoids in their non-psychoactive form (known as mixed carboxylates) and 5mg.
of a steam-distilled mixture of the natural terpenes and terpenoids found in cannabis and hemp. The terpene element is thought to be responsible for the increased medicinal efficacy of 'whole plant' cannabis preparations. The specific recipe is proprietary to Medical Greens.
SKTO president Artemus Mayor noted these products are game changers for patients.
"Now patients can accurately regulate their dosing with medication, without any worry of the psychoactive effects, or high, that is the natural byproduct of existing products on the market. We are fortunate that our team has been among the first to be able to enhance the consumer, and patient, experience in this manner," Mayor added.
Oct 10, 2013
OTC Disclosure & News Service
-
SKTO's Medical Greens Announces Licensing Agreement for Revolutionary New High Dose MMJ Delivery Option Dharmanol(TM)
LOS ANGELES, CA--(Marketwired - Oct 10, 2013) - SK3 Group, Inc.'s (OTC Pink: SKTO) subsidiary, Medical Greens, is pleased to announce that it has obtained the exclusive license for Dharmanol? for the State of California. Dr. Charles Apel of Berkeley Bio-Organic Research Laboratories has developed a proprietary technology to extract, stabilize, and preserve the medicinal cannabinoids found in hemp and marijuana in their non-psychoactive form. This technology allows patients to consume cannabinoid medicine without any of the "high" or "stoned" effects.?
"We consider this to be a major breakthrough in the treatment of cancer using cannabinoids. The results seen by those groups and individuals promoting the use of what has been dubbed 'Simpson' therapy have been very convincing. The problem, however, has been that many people who are fighting cancer, and have no experience with cannabis, cannot take the emotional and mental effects that come from following the regimen, which requires consumption of a gram of cannabis extract oil every day for several months. This is the equivalent of smoking up to 100 marijuana cigarettes every day. The "high" from the experience is truly overwhelming, and we have seen patients choose to discontinue the therapy, even though doing so likely leads to negative effects on their treatment," said D. Gold, Dr. Apel's partner in development of the process. "Now patients will be able to consume the large doses necessary for this therapy to be effective, with none of the psychoactive side effects that have been such an unforgiving part of the therapy."
Dharmanol? (pronounced DAR-mah-nol) will be available in two forms: low-dose non-psychoactive tablets and high-doses. The low-dose non-psychoactive tablets can be taken daily as a nutritional supplement to stimulate the endo-cannabinoid system, an internal system which controls and regulates many other bodily systems such as immune response.?Much research has shown that there is substantial medicinal benefit in "stimulating" a compromised endo-cannabinoid system with cannabinoids, causing the other systems to work as they should.
These tablets will contain an array of the most beneficial non-psychoactive cannabinoids.?Each tablet will contain 5 mg. of CBD, 5 mg. of mixed cannabinoids in their non-psychoactive form (known as mixed carboxylates) and 5 mg. of a steam-distilled mixture of the natural terpenes and terpenoids found in cannabis and hemp. The terpene element is thought to be responsible for the increased medicinal efficacy of "whole plant" cannabis preparations.
At the opposite end of the spectrum is using high dosage Dharmanol? much like the "Simpson" therapy. High doses can be taken daily with no psychoactive effects. On observing the positive results that patients are receiving with standard Simpson therapy, most people studying cannabis medicine agree that if the dose could be increased ten or a hundred times, its already substantial efficacy against cancer will be similarly enhanced. Now this is possible thanks to the removal of the "high" from the cannabinoids in the production of Dharmanol?.
"We believe that we have crossed the bridge, so to speak, between the incredible medicinal efficacy of the cannabis plant and the world of nutraceutical supplements. Now people will be able to benefit from the substantial health-giving aspects of the cannabis plant, without the 'high' and related side effects that have kept this wonderful herb from entering the world of mainstream medicine. Dr. Apel and I would like to thank all those who have worked so hard on this project to help us develop this new technology," said Gold.
"We are pleased to have acquired this exclusive license to this important new product in the fight against disease using medical cannabis," said Artemus Mayor, President of SK3 Group. "We expect it to be in high demand with collectives and consumers."
Dharmanol? tablets will be distributed through the collectives managed by or partnered with Medical Greens, which currently has products in over 75 collectives in the state of California.?The Manufacturer's Suggested Retail Price will be $25.00 per bottle for 8 capsules.
About SK3
SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.
AI
